Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.62 |
| ▸ | HTR2C | P28335 | 12/20 | 0.62 |
| ▸ | HTR2B | P41595 | 11/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL6603622 | 0.82 | HTR2A (0.67) | HTR2AHTR2CHTR2BCYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL6607986 | 0.81 | HTR2A (0.66) | HTR2AHTR2CHTR2BCYP3A4MAPT | |
| SCHEMBL6604307 | 0.77 | HTR2C (1.00) | HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL6603614 | 0.77 | HTR2C (1.00) | HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL6605040 | 0.77 | HTR2C (1.00) | HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL17296509 | 0.76 | HTR2C (0.63) | HTR2AHTR2CHTR2BCYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL6607981 | 0.76 | HTR2C (0.97) | HTR2AHTR2CHTR2BCYP3A4 | |
| Hydrochloric Acid SCHEMBL6604400 | 0.76 | HTR2C (0.97) | HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL6604236 | 0.74 | HTR2A (0.60) | HTR2AHTR2CHTR2BCYP3A4MAPT | |
| SCHEMBL4826871 | 0.74 | HTR2A (0.76) | HTR2AHTR2CHTR2BCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109809-B1 | PYRROLOQUINOLINES FOR TREATMENT OF OBESITY | CEREBRUS PHARM LTD (GB) | 2004-11-17 | — | — | EP | claimed |
| US-6365598-B1 | FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA | VERNALIS RESEARCH LIMITED (GB) | 2002-04-02 | — | — | US | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.